Advanced esophageal squamous cell cancer
Conditions
Interventions
Experimental group:Irinotecan plus raltitrexed
Sponsors
The First People's Hospital of Yancheng City, Jiangsu Province
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Pathologically confirmed advanced esophageal squamous cell carcinoma; 2. Received chemotherapy including Taxanes, platinum, or fluorouracil aged between 20 and 80 years; 3. Irinotecan and letitrexed have not been used before; 4. Easurable or assessable lesions by imaging studies according to the RECIST guidelin; 5. Eastern Cooperative Oncology Group (ECOG) performance status score less than 3;) 6. Hematology, biochemistry and organ function: (1) Adequate bone marrow function (hemoglobin level >= 90 g/L, (2) White blood cell count of 4-10x10^9/L, neutrophil count >= 1.5x10^9/L, (3) Platelet count >= 100x10^9/L); (4) Hepatic function (total bilirubin = 60 ml/min 7. Estimated life expectancy more than 3 months.
Exclusion criteria
Exclusion criteria: 1. Preexisted peripheral toxicity >= grade 2 of the National Cancer Institute Common Toxicity Criteria; 2. Central nervous system metastases; 3. Concurrent treatment that interfered with the study evaluation; 4. Acute infection; 5. Other uncontrolled underlying medical conditions that would impair the ability of the patients to receive the planned treatment; 6. Pregnant, and breastfeeding women or women of child-bearing potential without adequate contraception; 7. With other secondary malignant tumors; 8. Other incompatible cases considered by the researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PFS;OS; | — |
Countries
China
Contacts
Public ContactDai Xichao
The First People's Hospital of Yancheng City, Jiangsu Province
Outcome results
None listed